Literature DB >> 15621024

Effects of GABA(B), 5-HT(1A), and 5-HT(2) receptor stimulation on activation and inhibition of the rat lateral amygdala following medial geniculate nucleus stimulation in vivo.

David M Sokal1, Alessandra S Giarola, Charles H Large.   

Abstract

The input from the medial geniculate nucleus of the thalamus (MGN) to the lateral amygdala is known to be important in the regulation of fear and anxiety. Modulation of this pathway may be useful for the treatment of anxiety disorders. We set out to determine whether simple extracellular electrophysiological techniques could be used to study pharmacological modulation of this pathway in vivo. We studied the effects of GABA(B), 5-HT(1), and 5-HT(2) receptor agonists on activity in the lateral amygdala following stimulation of the MGN in isoflurane-anaesthetised rats. Electrical stimulation of the MGN evoked a characteristic biphasic field potential in the lateral amygdala. Baclofen (10 mg kg(-1), iv) inhibited the evoked potential with an effect that was most marked on the positive-going component (80+/-9% inhibition; P<0.05). Baclofen also significantly reduced paired-pulse inhibition of the negative-going component at short interpulse intervals (<200 ms). The 5-HT(1A) receptor ligands, 8-OH-DPAT (60 microg kg(-1), iv) and WAY-100635 (0.5 mg kg(-1), iv) were without effect on evoked responses or paired-pulse relationship. In contrast, the 5-HT(2) receptor agonist, DOI, caused a rapid inhibition of the field potential (to 59.33+/-11.41% of the baseline response; P<0.05). This effect was blocked by ketanserin, either following systemic (0.5 mg kg(-1), iv) or intra-amygdala administration. These results show that GABA(B) and 5-HT(2) receptor agonists can modulate activation of the lateral amygdala following MGN stimulation; furthermore, GABA(B) receptor agonists appear to have a profound effect on local circuit inhibition within the lateral amygdala. The results support the use of in vivo field potential recording within the MGN-lateral amygdala pathway to evaluate this as a possible site of action for novel anxiolytic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621024     DOI: 10.1016/j.brainres.2004.10.035

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.

Authors:  Fabienne Massé; Martine Hascoët; Eric Dailly; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

2.  Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice.

Authors:  Kevin K Ogden; Alpa Khatri; Stephen F Traynelis; Scott A Heldt
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

3.  Asymmetries in long-term and short-term plasticity at thalamic and cortical inputs to the amygdala in vivo.

Authors:  Torfi Siguròsson; Torfi Sigurdsson; Christopher K Cain; Valérie Doyère; Joseph E LeDoux
Journal:  Eur J Neurosci       Date:  2010-01-13       Impact factor: 3.386

Review 4.  Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions.

Authors:  Cristiano Bombardi; Giuseppe Di Giovanni
Journal:  Exp Brain Res       Date:  2013-04-17       Impact factor: 1.972

Review 5.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

Review 6.  Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex.

Authors:  Cristiano Bombardi
Journal:  Front Pharmacol       Date:  2014-04-09       Impact factor: 5.810

7.  Salicylate-induced auditory perceptual disorders and plastic changes in nonclassical auditory centers in rats.

Authors:  Guang-Di Chen; Kelly E Radziwon; Nina Kashanian; Senthilvelan Manohar; Richard Salvi
Journal:  Neural Plast       Date:  2014-05-07       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.